By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Human Genome Sciences, Inc. 

14200 Shady Grove Road

Rockville  Maryland  20850  U.S.A.
Phone: 301-309-8504 Fax: 301-309-8512

Human Genome Sciences (HGS) is located in the Washington, DC metro area, and was founded in 1992 with the goal of creating a global biopharmaceutical company to discover, develop, manufacture, and market gene-based drugs to address unmet medical needs. We have a significant product pipeline with seven products in clinical development, including drugs to treat hepatitis C, lupus and other autoimmune diseases, anthrax exposure, and cancer. In recent years, we have progressed toward becoming a late stage development and commercialization company, and we have recently started Phase 3 trials for three of our key development programs.

HGS is developing an innovative new treatment for systemic lupus erythematosus (SLE), which would be the first new treatment for lupus in nearly 40 years. This product, belimumab, is being co-developed and commercialized with Glaxo SmithKline. We are also developing a long-acting interferon alpha, Albuferon, for Hepatitis C, along with Novartis. HGS has also been awarded a two-phase contract with US government to supply them with ABthrax, a monoclonal antibody treatment for anthrax, for the Strategic National Stockpile, which we expect to deliver in 2008.

At HGS, people are the key to our success. We share a passion for scientific and business innovation, creating unique opportunities to contribute to the commercialization phase of our products. At HGS, you will have opportunities to learn and grow, interacting with talent of the highest caliber, and you will be supported by a culture committed to employee and leadership development. We offer a competitive salary and benefits package. HGS is an Equal Opportunity Employer EOE/AA M/F/D/V.

Please visit for further information on our company.

Key Statistics

Ownership: Public

Web Site: Human Genome Sciences, Inc.
Employees: 850+
Symbol: HGSI



SmithKline Beecham  Human Gene Consortium Partners

Sanofi-Synthelabo  Human Gene Consortium Partners

Takeda  Human Gene Consortium Partners

Pharmacia & Upjohn (Merged to form Pharmacia Corp)  Anti-Microbial Gene Partnerships

Roche (NJ)  Anti-Microbial Gene Partnerships

OraVax, Inc.  Anti-Microbial Gene Partnerships

Pasteur Merieux Connaught  Anti-Microbial Gene Partnerships

Vascular Genetics Inc.  Gene Therapy Partnerships

TRANSGENE  Gene Therapy Partnerships

GlaxoSmithKline (North Carolina) 

Novartis Corporation 

Company News
Anthrax Drug Brings $334 Million to Pentagon Advisor's Biotech Firm - Human Genome Sciences, Inc. (HGSI) 5/20/2013 9:14:07 AM
Human Genome Sciences, Inc. (HGSI) to Lay Off 97 Workers 10/18/2012 8:05:37 AM
4-Antibody AG Receives Additional Milestone Payments From Human Genome Sciences, Inc. (HGSI) 10/8/2012 10:50:02 AM
Human Genome Sciences, Inc. (HGSI) to Cut 114 Positions 9/6/2012 8:14:52 AM
GlaxoSmithKline (GSK) Completes $3.6 Billion Takeover of Human Genome Sciences, Inc. (HGSI) 8/6/2012 7:03:36 AM
Exclusive: Human Genome Sciences, Inc. (HGSI) Rejected Amgen (AMGN)'s $7 Billion Bid in 2010 7/27/2012 6:57:17 AM
3 Lessons From GlaxoSmithKline (GSK)'s Purchase of Human Genome Sciences, Inc. (HGSI) 7/17/2012 8:10:12 AM
GlaxoSmithKline (GSK) Clinches Deal to Buy Human Genome Sciences, Inc. (HGSI) for $2.8 Billion 7/16/2012 6:48:54 AM
Human Genome Sciences, Inc. (HGSI) Release: Survey Shows the Burden of Lupus on Work and Wallet 7/11/2012 12:05:18 PM
FYI From Human Genome Sciences, Inc. (HGSI): GlaxoSmithKline (GSK) Announces Positive Data from Harmony 8 Phase 3 Trial and Completion of Clinical Registration Package for Albiglutide in Type 2 Diabetes 7/11/2012 10:09:28 AM